In This Article:
Intelligent Bio Solutions Inc. INBS recently announced that it has secured a key patent in the United States relating to the Intelligent Fingerprinting Drug Screening Cartridge. This is the company’s sixth active patent to be granted in the United States, strengthening the protection of its unique and proprietary drug screening technology.
With this strategic milestone, INBS aims to enhance its competitive edge in the industry while accelerating the commercialization of the technology. As the company moves closer to market launch, the strengthened intellectual property (“IP”) protection underscores confidence in its product's potential impact.
Likely Trend of INBS Stock Following the News
Following the announcement, shares of the company tumbled 5.1% and closed at $1.67 yesterday. In the past six months, INBS’ shares have lost 8.2% compared with the industry’s 13.2% decline. The S&P 500 improved 1% in the same time frame.
However, securing a key U.S. patent strengthens INBS’ competitive edge by protecting its proprietary technology, reducing the risk of imitation and reinforcing investor confidence in long-term growth potential. This milestone enhances the company’s positioning ahead of its 2025 drug screening market entry, increasing the likelihood of successful commercialization and potential partnerships. As demand for innovative biometric diagnostic solutions rises, a strong IP portfolio can attract institutional investors, improve market perception and drive sustainable revenue growth, ultimately boosting the performance of the INBS stock over time.
Meanwhile, INBS currently has a market capitalization of $11.9 billion. The company expects an earnings growth of 80.4% in 2025.
Image Source: Zacks Investment Research
More on INBS’ Intelligent Fingerprinting Drug Screening Cartridge
INBS has developed a robust IP portfolio to safeguard its innovative drug screening technology. The company has been granted six active U.S. patents, each covering distinct aspects of its Intelligent Fingerprinting Drug Screening System. These patents encompass the proprietary lateral flow test strip within the Drug Screening Cartridge, the Sample Collection Cartridge, the cartridge housing and the buffer clip design. This comprehensive IP protection reinforces INBS' competitive position as it prepares to enter the U.S. drug screening market in 2025.
INBS’ Intelligent Fingerprinting Drug Screening Cartridge is a cutting-edge, non-invasive drug testing solution, designed to detect drug metabolites through fingerprint sweat analysis. Unlike traditional urine or blood tests, this innovative approach offers rapid, hygienic and user-friendly screening, making it ideal for workplace testing, law enforcement, rehabilitation programs and clinical applications.